Posts tagged ‘Michael J Fox Foundation’
April 9th, 2011
Parkinson’s disease is debilitating with no known cure. In a timely post for Parkinson’s disease awareness month, Pieter Droppert on Biotech Strategy Blog asks Dr Todd Sherer, Chief Program Officer of the Michael J. Fox Foundation, why we don’t have a cure and where the next major breakthrough will come from?
In the interview, Dr Sherer discusses the hope that biomarkers may offer. You can read more on Biotech Strategy Blog.
March 31st, 2011
What drives many of us who work in the life science, medical device, pharmaceutical or biotechnology industries is making a difference to the lives of patients through what we do. One organization that embodies this philosophy is the Michael J. Fox Foundation.
Pieter Droppert recently interviewed Dr Todd Sherer, the foundation’s Chief Program Officer. In the first of a two part interview on Biotech Strategy Blog, Dr Sherer explained their approach to funding of Parkinson’s disease research.
Michael J Fox Foundation announces positive results from Allon Therapeutics with davunetide in Parkinson's Disease
February 24th, 2011
The Michael J Foundation announced earlier this month positive preclinical data with davunetide in a mouse model of Parkinson’s Disease.
The drug is in clinical development by Vancouver based Allon Therapeutics for Alzheimer’s disease and other neurodegenerative disorders.
More about this interesting new product, its neuroprotective action and potential to slow down memory loss and cognitive decline can be found on Biotech Strategy Blog.